Wilson I. Gonsalves, MD
Mayo Clinic
Rochester, MN, USA

Background: Human adipocytes can contribute directly to the in vitro growth and progression of multiple myeloma (MM) cell lines. Clinically, an elevated body mass index (BMI) has been associated with an increased risk of MGUS and a shorter time to progression (TTP) of MGUS to MM. However, the impact of BMI on the risk of early progression to MM from a more advanced plasma cell disorder such as smoldering MM (SMM) remains unknown.

Conclusions: SMM pts with an elevated BMI appear to have a higher risk of early progression to MM than those with a normal BMI. This study provides evidence of a potentially modifiable risk factor for the progression of SMM to MM and warrants confirmation in larger studies.

Author(s): Wilson I. Gonsalves, S. Vincent Rajkumar, Angela Dispenzieri, Martha Lacy, Francis Buadi, David Dingli, Ronald S. Go, Prashant Kapoor, Suzanne R. Hayman, John Anthony Lust, Nelson Leung, Stephen J. Russell, Steven R. Zeldenrust, Yi Lin, Yi Lisa Hwa, Taxiarchis Kourelis, Robert A. Kyle, Morie A. Gertz, Shaji Kumar


Dr. Wilson I. Gonsalves, M.D., is a Senior Associate Consultant, Division of Hematology, Department of Internal Medicine, at the Mayo Clinic in Rochester, Minnesota. His main areas of focus include plasma cell metabolism, supportive care in plasma cell disorders, and population-based outcomes in plasma cell disorders. View Dr. Wilson I. Gonsalves full biography here.

Previous Post
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001)
Next Post
If I have a sustained remission and am on Revlimid, should I continue using it?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.